Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 6/20 | 0.34 |
| ▸ | PDE4A | P27815 | 2/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.30 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
| ▸ | PDE1A | P54750 | 1/20 | 0.30 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.30 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21748352 | 0.84 | ADORA2A (0.40) | PNPADORA2AADORA2B | |
| SCHEMBL8423728 | 0.81 | PDE4A (0.38) | PNPPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5503490 | 0.79 | ADORA2A (0.49) | PNPPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7617790 | 0.79 | PNP (0.36) | PNPPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6694607 | 0.79 | CYP3A4 (0.35) | ADORA2B | |
| SCHEMBL16106177 | 0.78 | ADORA2A (0.37) | PDE4APDE4BPDE4CPDE4DADORA2A | |
| SCHEMBL9960806 | 0.77 | PNP (0.38) | PNPPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6434440 | 0.75 | PNP (0.50) | PNPPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL874734 | 0.74 | ADORA2A (0.45) | PNPPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2113436 | 0.74 | ADORA2A (0.33) | PNPPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541600-B2 | 11-aza, 11-thia and 11-oxa sterol compounds and compositions | Harbor Therapeutics, Inc. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120101052-A9 | 15-THIA STEROID COMPOUNDS AND COMPOSITIONS | BIOVIE INC. | 2012-04-26 | — | — | US | disclosed |
| US-20120041016-A1 | 11-Aza, 11-Thia and 11-Oxa Sterol Compounds and Compositions | BIOVIE INC. | 2012-02-16 | — | — | US | disclosed |
| US-8022234-B2 | Compounds and compositions | HARBOR BIOSCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20110218162-A1 | 15-THIA STEROID COMPOUNDS AND COMPOSITIONS | FRINCKE JAMES M | 2011-09-08 | — | — | US | disclosed |
| US-7947846-B2 | 15-OXA-steroid compounds | HARBOR BIOSCIENCES, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20110009372-A1 | Compounds and compositions | BIOVIE INC. | 2011-01-13 | — | — | US | disclosed |
| US-20100222425-A1 | COMPOSITIONS AND TREATMENT METHODS-2 | BIOVIE INC. | 2010-09-02 | — | — | US | disclosed |
| US-20070275936-A1 | Formulations and Treatment Methods | BIOVIE INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070129282-A1 | Pharmaceutical treatments and compositions | BIOVIE INC. | 2007-06-07 | — | — | US | disclosed |
| US-20060079492-A1 | Compositions and treatment methods | BIOVIE INC. | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009372-A1 | Compounds and compositions | HSD3B1, CYP17A1, HSD17B1 | PNP 4748/4885PDE4A 564/4885PDE4B 683/4885 |
| US-20070129282-A1 | Pharmaceutical treatments and compositions | HSD3B1, HSD3B2, HSD17B1 | PNP 4773/4885PDE4A 657/4885PDE4B 847/4885 |
| US-20100222425-A1 | COMPOSITIONS AND TREATMENT METHODS-2 | MPL, THPO, HSD3B2 | PNP 1641/4885PDE4A 1426/4885PDE4B 1211/4885 |
| US-20060079492-A1 | Compositions and treatment methods | MPL, HPGDS, THPO | PNP 1245/4885PDE4A 1036/4885PDE4B 996/4885 |
| US-20120101052-A9 | 15-THIA STEROID COMPOUNDS AND COMPOSITIONS | MPL, THPO, ALOX15 | PNP 1521/4885PDE4A 956/4885PDE4B 1035/4885 |
| US-20120041016-A1 | 11-Aza, 11-Thia and 11-Oxa Sterol Compounds and Compositions | CYP51A1, HSD11B1, HSD3B1 | PNP 4133/4885PDE4A 233/4885PDE4B 247/4885 |
| US-20110218162-A1 | 15-THIA STEROID COMPOUNDS AND COMPOSITIONS | MPL, THPO, ALOX15 | PNP 1521/4885PDE4A 956/4885PDE4B 1035/4885 |
| US-20070275936-A1 | Formulations and Treatment Methods | HSD3B1, HSD17B1, HSD17B3 | PNP 4828/4885PDE4A 902/4885PDE4B 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.